We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cizzle Biotechnology (CIZ) Ord 0.01p

Sell:1.70p Buy:1.80p 0 Change: No change
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1.70p
Buy:1.80p
Change: No change
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1.70p
Buy:1.80p
Change: No change
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.

Contact details

Address:
6th Floor, 60 Gracechurch Street
LONDON
EC3V 0HR
United Kingdom
Telephone:
+44 (020) 74690930
Website:
https://cizzlebiotechnology.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 30 September 2024 30/09/24
AGM 24 June 2024 24/06/24

General stock information

EPIC:
CIZ
ISIN:
GB00BNG2VN02
Market cap:
£6.94 million
Shares in issue:
396.39 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Allan Syms
    Executive Chairman of the Board
  • Nigel Lee
    Finance Director, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.